Mukesh Ambani Headed Reliance Life Sciences To Conduct Trials for COVID-19 Vaccine
After the telecom, energy, and natural gas sector, the Reliance industry, owned by Indian businessman Mukesh Ambani, has now stepped into COVID-19 vaccine manufacturing.
After the Subject Expert Committee (SEC) reviewed its application, the drug regulator body, on Thursday, gave a green signal to Reliance Life Sciences' to perform clinical trials of its recombinant protein-based coronavirus pandemic vaccine candidate.
As per a report by a leading media house, Ambani-led Reliance filed an application seeking approval to conduct a Phase 1 trial from a drug regulatory body for its two-dose COVID-19 vaccine.
By conducting the first phase of the trial, the company wants to gather data and information about tolerability, safety pharmacokinetics and mechanism of action of drugs. After the success of the first phase, Reliance will move forward and apply for second and third phase trials.
However, Reliance Life Sciences has not made any official announcement about this development.
Talking about the present time, there are a total number of six vaccines that have got emergency use authorisation like Bharat Biotech's Covaxin, Russia’s Sputnik V, Serum Institute’s Covishield, Moderna’s, Johnson & Johnson’s, and Cadila’s were approved last week.
Meanwhile, As per the Union Health and Family Welfare Ministry, India registered a total of 44,658 fresh COVID-19 cases and 496 deaths in the last 24 hours. This has pushed the total of the country to 3,26,03,188, while the death toll has gone up to 4,36,861.
